Primary completion· ClinicalTrials.gov
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
Secukinumab History and Updates
226 events · 2010 – present
Synced daily from openFDA and ClinicalTrials.gov. Last sync: .
35
FDA Approvals
0
Label Revisions
631
Trial Milestones
7
Pivotal Publications
Source: openFDA, ClinicalTrials.gov via AACT, PubMed · Hipa.ai, 2026-06-08Download chart as PNG
This page tracks every FDA action, clinical trial milestone, and major publication for Secukinumab since 2010, drawn from openFDA, ClinicalTrials.gov, and PubMed.
All published updates (24)
2026
- Results postedSecukinumab + Lifestyle Intervention Improves Psoriasis, Cardiometabolic Markers· Apr 22, 2026
- FDA approval (supplemental)Cosentyx (Secukinumab) Receives FDA Supplemental Approval for Efficacy· Apr 17, 2026
- FDA approval (supplemental)Cosentyx (secukinumab) Receives FDA Supplemental Approval for Efficacy· Apr 17, 2026
- FDA approval (supplemental)Cosentyx (Secukinumab) FDA Approves Supplemental Efficacy Application· Mar 12, 2026
- Primary completionSecukinumab Phase 3 Trial for Giant Cell Arteritis Completes Primary Phase· Feb 24, 2026
- Primary completionSecukinumab Biosimilar Trial for Plaque Psoriasis Completes Phase 3 Primary…· Feb 18, 2026
- Results postedSecukinumab achieves 60.10% ASAS40 response in nr-axSpA vs 24.78% for placebo· Jan 30, 2026
2025
- Results postedSecukinumab Rotator Cuff Tendinopathy Phase 3 Trial Data Posted· Dec 18, 2025
- Results postedSecukinumab Trial Shows Greater WORC Score Improvement in Rotator Cuff…· Dec 2, 2025
- Results postedSecukinumab Phase 3 Trial for Rotator Cuff Tendinopathy Terminated· Dec 2, 2025
- Results postedSecukinumab Shows Improved Psoriatic Arthritis HAQ-DI Response vs. Ustekinumab· Oct 16, 2025
- Primary completionSecukinumab Phase 3 Trial for Polymyalgia Rheumatica Completes Primary Phase· Sep 10, 2025
- Primary completionSecukinumab: Phase 3 Comparative Study for Plaque Psoriasis Completes· Jun 30, 2025
- Results postedSecukinumab Trial: Psoriasis Patients Show Changes in Itch and Pain Scores· Jun 5, 2025
- Results postedSecukinumab Achieves 100% JIA ACR 30 Response in JPsA and ERA Trial· May 23, 2025
- Primary completionSecukinumab: Phase 3 Psoriasis Trial Reaches Primary Completion· Apr 30, 2025
- Primary completionSecukinumab Phase 3 GCA Trial Completes Primary Data Collection· Apr 11, 2025
2021
- Pivotal publicationSecukinumab: Plaque Psoriasis Study Compares Against Bimekizumab· Jan 1, 2021
2020
- Pivotal publicationSecukinumab Compared to Adalimumab for Active Psoriatic Arthritis in Phase 3b…· Jan 1, 2020
2019
- Pivotal publicationSecukinumab: ECLIPSE Trial Compares Efficacy Against Guselkumab in Psoriasis· Jan 1, 2019
2015
- Pivotal publicationSecukinumab (Cosentyx) Efficacy in Psoriatic Arthritis Published· Jan 1, 2015
- Pivotal publicationSecukinumab (Cosentyx) FUTURE 2 Trial Shows Efficacy in Psoriatic Arthritis· Jan 1, 2015
- Pivotal publicationSecukinumab for Ankylosing Spondylitis: Pivotal Efficacy and Safety Results· Jan 1, 2015
2014
- Pivotal publicationSecukinumab Phase 3 Trials Show Results for Plaque Psoriasis· Jan 1, 2014
Upcoming & expected milestones
Trial started· ClinicalTrials.gov
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
Trial started· ClinicalTrials.gov
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Trial started· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Primary completion· ClinicalTrials.gov
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Primary completion· ClinicalTrials.gov
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Sup
Primary completion· ClinicalTrials.gov
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Primary completion· ClinicalTrials.gov
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Primary completion· ClinicalTrials.gov
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Primary completion· ClinicalTrials.gov
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) i
Primary completion· ClinicalTrials.gov
IL-17 Blockade to Decrease irAEs (REPLAY)
Primary completion· ClinicalTrials.gov
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
Primary completion· ClinicalTrials.gov
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Primary completion· ClinicalTrials.gov
Immunoclassification of Psoriasis: a Strategy for Precision Medicine
Primary completion· ClinicalTrials.gov
Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis
Primary completion· ClinicalTrials.gov
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remiss
Primary completion· ClinicalTrials.gov
Proactive TDM Versus Standard Use of Biologics in Psoriasis
Primary completion· ClinicalTrials.gov
Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
Primary completion· ClinicalTrials.gov
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remiss
Primary completion· ClinicalTrials.gov
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Primary completion· ClinicalTrials.gov
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Primary completion· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Primary completion· ClinicalTrials.gov
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Primary completion· ClinicalTrials.gov
Secukinumab Open Label Roll-over Extension Protocol
Primary completion· ClinicalTrials.gov
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Primary completion· ClinicalTrials.gov
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participan
Past events
2026
Primary completion· ClinicalTrials.gov
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antib
Primary completion· ClinicalTrials.gov
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
Primary completion· ClinicalTrials.gov
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Primary completion· ClinicalTrials.gov
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
Trial started· ClinicalTrials.gov
IL-17 Blockade to Decrease irAEs (REPLAY)
Results posted· ClinicalTrials.gov
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psorias
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Efficacy.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Efficacy.
Trial started· ClinicalTrials.gov
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Trial registered· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa
Trial registered· ClinicalTrials.gov
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
Trial registered· ClinicalTrials.gov
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Efficacy.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Primary completion· ClinicalTrials.gov
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
Results posted· ClinicalTrials.gov
Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
Trial registered· ClinicalTrials.gov
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
Trial started· ClinicalTrials.gov
Utilization of a Microdevice for Psoriasis and Atopic Dermatitis
2025
Trial started· ClinicalTrials.gov
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) i
Results posted· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Trial started· ClinicalTrials.gov
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
Trial registered· ClinicalTrials.gov
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Results posted· ClinicalTrials.gov
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
Results posted· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Trial started· ClinicalTrials.gov
Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS
Primary completion· ClinicalTrials.gov
Personalized Therapies in Inflammatory Complex Disease
Trial registered· ClinicalTrials.gov
Pharmacokinetic, Safety and Immunogenicity Study of New Process CMAB015 and Cosentyx in Healthy Volunteers
Trial registered· ClinicalTrials.gov
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) i
Primary completion· ClinicalTrials.gov
Personalized Therapies in Inflammatory Complex Disease
Trial registered· ClinicalTrials.gov
IL-17 Blockade to Decrease irAEs (REPLAY)
Results posted· ClinicalTrials.gov
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
Trial started· ClinicalTrials.gov
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Trial started· ClinicalTrials.gov
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participan
Primary completion· ClinicalTrials.gov
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Pol
Trial registered· ClinicalTrials.gov
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
Trial registered· ClinicalTrials.gov
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Trial registered· ClinicalTrials.gov
To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects
Primary completion· ClinicalTrials.gov
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
Results posted· ClinicalTrials.gov
Brain Changes in Psoriasis After Secukinumab Treatment
Trial started· ClinicalTrials.gov
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Trial started· ClinicalTrials.gov
Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa
Primary completion· ClinicalTrials.gov
Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
Trial started· ClinicalTrials.gov
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antib
Trial started· ClinicalTrials.gov
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
Results posted· ClinicalTrials.gov
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of LZM012
Trial registered· ClinicalTrials.gov
A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antib
Results posted· ClinicalTrials.gov
AScalate: Treat-to-target in Axial Spondyloarthritis
Trial registered· ClinicalTrials.gov
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Primary completion· ClinicalTrials.gov
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia
Trial started· ClinicalTrials.gov
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Trial registered· ClinicalTrials.gov
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Primary completion· ClinicalTrials.gov
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Trial started· ClinicalTrials.gov
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
Trial registered· ClinicalTrials.gov
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis
Primary completion· ClinicalTrials.gov
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
Trial registered· ClinicalTrials.gov
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Results posted· ClinicalTrials.gov
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
2024
Primary completion· ClinicalTrials.gov
The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
Primary completion· ClinicalTrials.gov
Efficacy and Safety of Secukinumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa
Trial registered· ClinicalTrials.gov
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participan
Trial started· ClinicalTrials.gov
Proactive TDM Versus Standard Use of Biologics in Psoriasis
Primary completion· ClinicalTrials.gov
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
Trial started· ClinicalTrials.gov
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Sup
Trial registered· ClinicalTrials.gov
A Randomized Trial Comparing the Efficacy and Safety of Secukinumab with Tofacitinib in the Treatment of Moderate to Severe Hidradenitis Sup
Primary completion· ClinicalTrials.gov
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Primary completion· ClinicalTrials.gov
Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment
Primary completion· ClinicalTrials.gov
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
Primary completion· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Primary completion· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Results posted· ClinicalTrials.gov
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nep
Trial registered· ClinicalTrials.gov
A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Results posted· ClinicalTrials.gov
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to
Results posted· ClinicalTrials.gov
This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS).
Primary completion· ClinicalTrials.gov
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Trial registered· ClinicalTrials.gov
Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
Results posted· ClinicalTrials.gov
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
Primary completion· ClinicalTrials.gov
To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects
Trial started· ClinicalTrials.gov
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
Primary completion· ClinicalTrials.gov
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Sub
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Trial started· ClinicalTrials.gov
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Results posted· ClinicalTrials.gov
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjec
Trial started· ClinicalTrials.gov
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Primary completion· ClinicalTrials.gov
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
Results posted· ClinicalTrials.gov
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Primary completion· ClinicalTrials.gov
Brain Changes in Psoriasis After Secukinumab Treatment
Trial registered· ClinicalTrials.gov
Proactive TDM Versus Standard Use of Biologics in Psoriasis
Trial registered· ClinicalTrials.gov
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
Trial registered· ClinicalTrials.gov
Biologic Therapy for Generalized Pustular Psoriasis
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Primary completion· ClinicalTrials.gov
COVID-19 VaccinE Response in Rheumatology Patients
Primary completion· ClinicalTrials.gov
Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
Trial started· ClinicalTrials.gov
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Trial registered· ClinicalTrials.gov
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
Trial started· ClinicalTrials.gov
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Sub
Results posted· ClinicalTrials.gov
A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)
Trial started· ClinicalTrials.gov
Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis
Results posted· ClinicalTrials.gov
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Act
Trial started· ClinicalTrials.gov
To Compare the Pharmacokinetics, Safety and Immunogenicity of CT-P55 and Cosentyx in Healthy Subjects
2023
Primary completion· ClinicalTrials.gov
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Mod
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Trial registered· ClinicalTrials.gov
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Trial registered· ClinicalTrials.gov
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Sub
Trial registered· ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of LZM012
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Efficacy.
FDA approval· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Type 3 - New Dosage Form.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
Primary completion· ClinicalTrials.gov
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
Primary completion· ClinicalTrials.gov
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nep
Primary completion· ClinicalTrials.gov
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
Results posted· ClinicalTrials.gov
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
Trial started· ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of LZM012
Primary completion· ClinicalTrials.gov
Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
Trial started· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Results posted· ClinicalTrials.gov
Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS)
Trial started· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Labeling.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Manufacturing (CMC).
Primary completion· ClinicalTrials.gov
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
Trial registered· ClinicalTrials.gov
Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.
Primary completion· ClinicalTrials.gov
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjec
Primary completion· ClinicalTrials.gov
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Efficacy.
Primary completion· ClinicalTrials.gov
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
Results posted· ClinicalTrials.gov
A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis
Trial started· ClinicalTrials.gov
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remiss
Trial started· ClinicalTrials.gov
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Pol
Trial registered· ClinicalTrials.gov
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Pol
Trial registered· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Primary completion· ClinicalTrials.gov
Scientific Substantiation and Assessment of the Effectiveness of Pathogenetic Methods of Therapy for Congenital Ichthyosis in Children
Trial registered· ClinicalTrials.gov
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
Trial started· ClinicalTrials.gov
Pharmacokinetic, Safety and Immunogenicity Study of CMAB015 and Cosentyx in Healthy Volunteers
Trial registered· ClinicalTrials.gov
Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy
Trial registered· ClinicalTrials.gov
Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): S
Trial registered· ClinicalTrials.gov
Secukinumab in Active Non-segmental Vitiligo
Trial started· ClinicalTrials.gov
Immunoclassification of Psoriasis: a Strategy for Precision Medicine
2022
Primary completion· ClinicalTrials.gov
Biologic Therapy for Generalized Pustular Psoriasis
Trial registered· ClinicalTrials.gov
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
Trial started· ClinicalTrials.gov
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
Trial registered· ClinicalTrials.gov
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remiss
Primary completion· ClinicalTrials.gov
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
Primary completion· ClinicalTrials.gov
An Efficacy Study of Secukinumab In Enthesitis of Psoriatic Arthritis Patients
Trial started· ClinicalTrials.gov
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
Trial registered· ClinicalTrials.gov
Managed Access Programs for AIN457, Secukinumab
Trial started· ClinicalTrials.gov
Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database
Results posted· ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chroni
Trial registered· ClinicalTrials.gov
Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy
Primary completion· ClinicalTrials.gov
PsA Secukinumab XCT Structural Progression Study
Trial started· ClinicalTrials.gov
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Trial registered· ClinicalTrials.gov
The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
Trial registered· ClinicalTrials.gov
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
Trial registered· ClinicalTrials.gov
Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis
Trial started· ClinicalTrials.gov
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
Trial started· ClinicalTrials.gov
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
Trial registered· ClinicalTrials.gov
Immunoclassification of Psoriasis: a Strategy for Precision Medicine
Trial started· ClinicalTrials.gov
Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
Results posted· ClinicalTrials.gov
Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Trial started· ClinicalTrials.gov
Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects
Primary completion· ClinicalTrials.gov
Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.
Trial registered· ClinicalTrials.gov
Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission
Trial registered· ClinicalTrials.gov
Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients
Trial registered· ClinicalTrials.gov
Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)
Results posted· ClinicalTrials.gov
Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankyl
Primary completion· ClinicalTrials.gov
EBIO - Enthesitis Biopsy Study
Trial registered· ClinicalTrials.gov
A Study Evaluating the Efficacy of Secukinumab 300mg in Chinese Adults With Active Ankylosing Spondylitis
Trial started· ClinicalTrials.gov
The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients
Primary completion· ClinicalTrials.gov
A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis
Primary completion· ClinicalTrials.gov
Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Act
Trial registered· ClinicalTrials.gov
Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis
Trial started· ClinicalTrials.gov
Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)
Primary completion· ClinicalTrials.gov
AScalate: Treat-to-target in Axial Spondyloarthritis
Trial registered· ClinicalTrials.gov
Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).
Primary completion· ClinicalTrials.gov
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris
2021
Primary completion· ClinicalTrials.gov
Oral Chinese Herbal Medicine Concurrent With Secukinumab for Severe Plaque Psoriasis
Primary completion· ClinicalTrials.gov
Secukinumab (Cosentyx®) Effectiveness in Axial Spondyloarthritis and Psoriatic Arthritis Patients Using Artificial Intelligence (SpAINET): S
Primary completion· ClinicalTrials.gov
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
Primary completion· ClinicalTrials.gov
Methotrexate Versus Secukinumab Safety in Psoriasis Patients With Metabolic Syndrome
Primary completion· ClinicalTrials.gov
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Efficacy.
FDA approval (supplemental)· FDA
Sponsor: NOVARTIS PHARMS CORP. Class: Efficacy.
Results posted· ClinicalTrials.gov
Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)
Primary completion· ClinicalTrials.gov
Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to
Primary completion· ClinicalTrials.gov
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psorias
Trial started· ClinicalTrials.gov
A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED)
Primary completion· ClinicalTrials.gov
PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus
Trial started· ClinicalTrials.gov
COVID-19 VaccinE Response in Rheumatology Patients
Results posted· ClinicalTrials.gov
Safety and Efficacy of Secukinumab in Mild Psoriasis
Sources
FDA approvals, label revisions, and recalls come from the public openFDA APIs (Drugs@FDA, Drug Label, Drug Enforcement). Drug-safety communications come from the FDA RSS feed. Trial milestones come from ClinicalTrials.gov via the AACT pg dump. Pivotal-publication events come from PubMed, filtered to high-impact journals linked to a Phase 3 trial in our inventory.